hit counter
BioXcel Therapeutics, Inc. (BTAI) Stock News Sentiment & Price - Sentifly
BTAI - Sentifly


Profile

Watchlist

Your watchlist is empty. Go add some tickers to it!



BioXcel Therapeutics, Inc. (BTAI)

USA
Biotechnology
NASDAQ
BTAI Price and Sentiment
1MO
1D
Positive, Negative
Loading chart...
BTAI Latest news
GlobeNewsWire
Neutral
BioXcel Therapeutics to Present at the 2021 Jefferies London Healthcare Conference
2021-11-11 07:00

NEW HAVEN, Conn., Nov. 11, 2021 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology, today announced that Vimal Mehta, Ph.D., Founder and Chief Executive Officer, and Frank Yocca, Ph.D., Chief Scientific Officer , will participate in a fireside chat at the 12th Annual Jefferies Global Healthcare Conference in London on Wednesday, November 17, 2021 at 4:20 p.m. GMT / 11:20 a.m. ET. Dr. Mehta and Dr. Yocca will highlight the Company's neuroscience and immune-oncology programs, artificial intelligence platform used to augment and accelerate the drug candidate discovery and development process, and its commercial and launch readiness plans for BXCL501.

Seeking Alpha
Neutral
BioXcel Therapeutics, Inc. (BTAI) CEO Vimal Mehta on Q3 2021 Results - Earnings Call Transcript
2021-11-10 12:25

BioXcel Therapeutics, Inc. (BTAI) CEO Vimal Mehta on Q3 2021 Results - Earnings Call Transcript

GlobeNewsWire
Neutral
BioXcel Therapeutics Reports Third Quarter 2021 Financial Results and Recent Operational Highlights
2021-11-10 07:00

Plans for commercial and launch readiness advancing for BXCL501 orally dissolving film, for the acute treatment of agitation associated with schizophrenia and bipolar disorders I and II, ahead of January 5, 2022 PDUFA date

GlobeNewsWire
Neutral
BioXcel Therapeutics to Report Third Quarter 2021 Financial Results on November 10, 2021
2021-10-27 07:00

NEW HAVEN, Conn., Oct. 27, 2021 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology, today announced that it will release its third quarter 2021 financial results on Wednesday, November 10, 2021 before the open of the U.S. financial markets. BioXcel Therapeutics' management team will also host a conference call and webcast at 8:30 AM ET to discuss the Company's financial results and to provide a general business update.

Seeking Alpha
Positive
BioXcel Therapeutics: Ready To Enter The Depression Therapeutic Field
2021-10-24 03:48

The company intends to expand the indication of BXCL501 to treat anxious depression.

The Motley Fool
Positive
This High-Risk, High-Reward Stock Might Double Your Money
2021-10-20 10:00

After a difficult year, shares of this biotech could bounce back big.

GlobeNewsWire
Neutral
BioXcel Therapeutics Announces Expansion of Phase 2 Trial of BXCL701 in De Novo and Treatment-Emergent Small-Cell Neuroendocrine Prostate Cancer
2021-10-18 07:00

Initial findings from Phase 1b/2 trial of BXCL701 in combination with KEYTRUDA met efficacy threshold to support expansion of existing cohort of de novo and treatment-emergent Small-Cell Neuroendocrine Prostate Cancer (SCNC)

The Motley Fool
Negative
Why BioXcel Therapeutics Stock Is Sinking Today
2021-10-14 11:39

The company's chief commercial officer resigned.

GlobeNewsWire
Neutral
BioXcel Therapeutics to Highlight Novel Approaches in AI-Based Drug Candidate Discovery and Development and Advances in Neuroscience Portfolio at Virtual R&D Day
2021-09-23 07:00

Management to showcase AI platform to develop potential treatments for neuropsychiatric disorders

GlobeNewsWire
Neutral
BioXcel Therapeutics Presents Results from Ongoing Phase 2 Trial of BXCL701 in Combination with KEYTRUDA® in Aggressive Forms of Prostate Cancer at ESMO
2021-09-15 18:06

BXCL701 plus KEYTRUDA® (pembrolizumab) demonstrates encouraging anti-tumor activity in heavily pre-treated mCRPC patients with adenocarcinoma

Loading more news...